文献速递消化系统肿瘤胸部肿瘤

恶性腹膜间皮瘤中ALK重排的鉴定

Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma.
PubMed 文献 · JAMA Oncol · 2018-01-01

该研究在2005至2015年单中心连续纳入88例腹膜间皮瘤患者,通过免疫组化筛选并经FISH确认ALK重排,发现11例(13%)ALK免疫组化阳性,其中3例弥漫强阳性者存在ATG16L1、STRN、TPM1等新型融合伴侣;ALK重排患者均为女性且更年轻(中位年龄36 vs 62,P=0.02),无石棉纤维暴露,且缺乏BAP1、SETD2、NF2等常见遗传学改变;205例胸膜间皮瘤均ALK阴性。

要点

  • 腹膜间皮瘤中ALK免疫组化阳性率为13%(11/88),其中3例弥漫强阳性者经FISH确认存在ALK重排。
  • ALK重排患者均为女性且更年轻(中位年龄36 vs 62,P=0.02),无石棉纤维暴露。
  • ALK重排的腹膜间皮瘤缺乏BAP1、SETD2、NF2等常见遗传学改变及9p/22q缺失。

核心结论

  • 在部分腹膜间皮瘤患者中鉴定出独特的ALK重排,这些病例均无石棉纤维、治疗性放疗及该肿瘤典型的细胞遗传学和分子改变。
  • 识别可临床干预的ALK重排可能代表恶性腹膜间皮瘤的一种新发病机制,并有望用于靶向治疗。

研究设计与样本

  • 研究为单中心连续病例系列,纳入2005至2015年诊断的88例腹膜间皮瘤患者(39例男性,49例女性;中位年龄61岁,范围17-84岁)。
  • 通过免疫组化识别ALK阳性间皮瘤,并用荧光原位杂交(FISH)确认ALK重排;对ALK重排病例采用肿瘤DNA和RNA的靶向下一代测序确定融合伴侣。
  • 在部分病例中通过联合扫描电子显微镜和X射线光谱法定量石棉纤维;并在另外205例胸膜间皮瘤患者中探索ALK重排。

主要发现

  • 免疫组化显示11例(13%)腹膜间皮瘤ALK阳性,其中8例为局灶弱阳性,3例为弥漫强阳性。
  • 局灶弱阳性病例中,FISH和下一代测序均未检测到ALK重排;弥漫强阳性病例经FISH确认ALK重排,下一代测序鉴定出新型融合伴侣ATG16L1、STRN和TPM1。
  • ALK重排的腹膜间皮瘤患者均为女性且较无ALK重排者年轻(中位年龄36 vs 62;Mann-Whitney检验,P=0.02),但其他临床病理特征(肿瘤结节大小、组织学、治疗和生存)无差异。
  • ALK重排病例中未检测到石棉纤维,且通常见于腹膜间皮瘤的染色体9p或22q区域缺失及BAP1、SETD2或NF2基因改变在ALK重排病例中均缺失。
  • 所有胸膜间皮瘤(205例)经免疫组化均为ALK阴性。

关键数值与推荐

  • ALK免疫组化阳性定义为11例(13%)腹膜间皮瘤,其中局灶弱阳性8例、弥漫强阳性3例。
  • ALK重排患者与无ALK重排患者的中位年龄分别为36岁和62岁(Mann-Whitney检验,P=0.02)。
  • ALK重排病例中未检测到石棉纤维;胸膜间皮瘤205例均ALK免疫组化阴性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Malignant peritoneal mesothelioma is a rare, aggressive tumor arising from the peritoneal lining, induced by asbestos, therapeutic radiation, or germline mutations. Nevertheless, the molecular features remain largely unknown. OBJECTIVE: To investigate anaplastic lymphoma kinase (ALK) rearrangements in a large series of peritoneal mesothelioma and characterize the mutational landscape of these tumors. DESIGN, SETTING, AND PARTICIPANTS: We studied 88 consecutive patients (39 men, 49 women; median age 61, range 17-84 years) with peritoneal mesotheliomas diagnosed at a single institution between 2005 and 2015. We identified ALK-positive mesotheliomas by immunohistochemistry and confirmed ALK rearrangement by fluorescence in situ hybridization (FISH). In ALK-rearranged cases, we characterized the fusion partners using targeted next-generation sequencing of both tumor DNA and RNA. In select cases, we quantified asbestos fibers by combined scanning electron microscopy and x-ray spectroscopy. We also explored ALK rearrangement in a separate series of 205 patients with pleural mesothelioma. MAIN OUTCOMES AND MEASURES: Identification and characterization of novel ALK rearrangements and correlations with clinicopathologic characteristics. RESULTS: Anaplastic lymphoma kinase was positive by immunohistochemistry in 11 (13%) peritoneal mesotheliomas (focal weak in 8, diffuse strong in 3). In focal weak ALK-positive cases, no ALK rearrangement was detected by FISH or next-generation sequencing. In strong diffuse ALK-positive cases, FISH confirmed ALK rearrangements, and next-generation sequencing identified novel fusion partners ATG16L1, STRN, and TPM1. Patients with ALK-rearranged peritoneal mesotheliomas were women and younger than patients without ALK rearrangement (median age 36 vs 62; Mann-Whitney test, P = .02), but all other clinicopathologic characteristics (size of tumor nodules, histology, treatment, and survival) were not different. No asbestos fibers were detected in ALK-rearranged cases. Furthermore, loss of chromosomal region 9p or 22q or genetic alterations in BAP1, SETD2, or NF2 typically present in peritoneal mesothelioma were absent in the ALK-rearranged cases. All pleural mesotheliomas were ALK-negative by immunohistochemistry. CONCLUSIONS AND RELEVANCE: We identified unique ALK rearrangements in a subset of patients with peritoneal mesothelioma, each lacking asbestos fibers, therapeutic radiation, and cytogenetic and molecular alterations typically found in these tumors. Identification of clinically actionable ALK rearrangements may represent a novel pathogenetic mechanism of malignant peritoneal mesothelioma with promise for targeted therapy.

来源:JAMA Oncol,查看原文。版权归原作者所有。

引用

  1. Hung YP, Dong F, Watkins JC, et al. Identification of ALK Rearrangements in Malignant Peritoneal Mesothelioma. JAMA Oncol. 2018. PMID: 28910456. doi:10.1001/jamaoncol.2017.2918

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。